Global Neuroendocrine Tumor Drug Market By Product Type (mTOR Protein Inhibitors, Tyrosine Kinase 3 Inhibitors) And By End-Users/Application (Hospital, Clinic) Global Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2013 - 2026

  • AMR-984665
  • April 2021
  • Pharmaceuticals
  • 139 Pages

Report Preview

The global Neuroendocrine Tumor Drug market research report provides complete study and detail analysis of the market. This study includes forecast analysis of the market which is based on global and regional level, whereas the research reports the provides forecast data from 2020-2028 and historic of 2018 and 2019. All the values are based on revenue USD Million. Moreover, the market research report describes various segments of the Neuroendocrine Tumor Drug market based on its types, applications and end-use industry. The applications of the market are explained in different industry verticals with reference to major countries across the globe. Along with this, the research report also covers all the major players that are operating in the global Neuroendocrine Tumor Drug market. These major players of the market are further studied and analyzed based on various parameters, such as annual market revenue, annual sales of the company, marketing strategy, historic growth and shipment volumes. Based on all the company’s insights, the market research analyst also suggests business strategy and marketing plans for improving the market position of existing participants of Neuroendocrine Tumor Drug market.

Apart from this, the market research report also covers drivers and restraints for the global Neuroendocrine Tumor Drug market and their impact on the demand and supply during the forecast period. Along with this, the research report also provides Neuroendocrine Tumor Drug market trends and opportunities that are based on regional and global level. Furthermore, the market research report also provides the major distributors and manufacturers that are operating in all the key region across the world. The researched data provided in the report is widely used by various industry players to strengthen their distribution channel and improve the geographical reach. In addition, the report also covers all the major players of the global Neuroendocrine Tumor Drug market and its key offerings and solutions. The report also provides recent mergers and acquisitions of these key players.

XYZ Market Strategic Analysis:
In 2019, the global XYZ market was valued at US$ xx Mn, and it is expected to reach at US$ xx Mn at a CAGR of xx% during 2020-2028.

The data which is provided in the market research report is analyzed and evaluated with the help of various marketing tools, such as SWOT analysis, Poster’s Five Force analysis, PESTEL analysis, value chain analysis, player positioning analysis and market share analysis. Therefore, this analysis tools helps the analyst to evaluate the Neuroendocrine Tumor Drug market based on various parameters such as capital investments, impact of consumer’s preferences, economies of scale, manufacturing rights and patents, existing distribution channels, switching costs, government regulations and brand loyalty. 
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2019
Forecast Period Covered 2019 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Product Type mTOR Protein Inhibitors, Tyrosine Kinase 3 Inhibitors, Somatostatin Receptor Antagonists, Growth Hormone Releasing Factor Antagonists, Somatostatin Receptor Agonists, Others
Applications Hospital, Clinic, Others
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered Eisai, Exelixis, Inc., Foresee Pharmaceuticals, LLC, Hutchison MediPharma Limited, Intezyne, Inc, INVENT Pharmaceuticals, Inc., Ipsen S.A., Jiangsu Hengrui Medicine Co., Ltd., Karyopharm Therapeutics, Inc., Lexicon Pharmaceuticals, Inc., Midatech Pharma Plc ., Millennium Pharmaceuticals, Inc., MolMed S.p.A., Northwest Biotherapeutics, Inc., Novartis AG, OctreoPharm Sciences GmbH, OXiGENE, Inc.

Neuroendocrine Tumor Drug Market Segment Analysis:
The Neuroendocrine Tumor Drug market research report segments the market based on its types, applications and end-use industry. All the segments of the market are analyzed and evaluated based on current and future trends of the market. The data for the segments and its categories is provided from 2018 to 2028. 

Neuroendocrine Tumor Drug Market, by Type: mTOR Protein Inhibitors, Tyrosine Kinase 3 Inhibitors, Somatostatin Receptor Antagonists, Growth Hormone Releasing Factor Antagonists, Somatostatin Receptor Agonists, Others

Neuroendocrine Tumor Drug Market, by Application: Hospital, Clinic, Others

Major Key Players for Global Neuroendocrine Tumor Drug Market:
The Neuroendocrine Tumor Drug market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Eisai, Exelixis, Inc., Foresee Pharmaceuticals, LLC, Hutchison MediPharma Limited, Intezyne, Inc, INVENT Pharmaceuticals, Inc., Ipsen S.A., Jiangsu Hengrui Medicine Co., Ltd., Karyopharm Therapeutics, Inc., Lexicon Pharmaceuticals, Inc., Midatech Pharma Plc ., Millennium Pharmaceuticals, Inc., MolMed S.p.A., Northwest Biotherapeutics, Inc., Novartis AG, OctreoPharm Sciences GmbH, OXiGENE, Inc.

Geographic Coverage for Neuroendocrine Tumor Drug Market:
The market research report on global Neuroendocrine Tumor Drug market offers complete analysis across various regions across the world. The Neuroendocrine Tumor Drug market is distributed into various regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The global leading market share as per the region is evaluated after considering Neuroendocrine Tumor Drug market revenue, sales, shares, recent developments, innovations and growth rates. This section of regional analysis provides widespread evaluation of the industry from various countries and regions.

North America Neuroendocrine Tumor Drug Market Value and Forecast
  • US
  • Canada

Europe Neuroendocrine Tumor Drug Market Value and Forecast
  • UK
  • Germany
  • France
  •  Rest of Europe

Asia Pacific Neuroendocrine Tumor Drug Market Value and Forecast
  • China
  • Japan
  • India
  • Rest of Asia Pacific

Latin America Neuroendocrine Tumor Drug Market Value and Forecast
  • Mexico
  • Brazil
  • Rest of Latin America

Middle East and Africa Neuroendocrine Tumor Drug Market Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa



Key highlights of the Neuroendocrine Tumor Drug market report:
  • The report provides key trends of the global Neuroendocrine Tumor Drug market
  • The report also covers consumer preferences and current industry growth
  • Key products or solutions offered by the main players in the Neuroendocrine Tumor Drug industry
  • The report covers all the recent developments of the Neuroendocrine Tumor Drug market and helps to provide current industry updates
  • The report covers a detailed look over the global Neuroendocrine Tumor Drug Industry and provides with significant actionable insights
  • The Neuroendocrine Tumor Drug market estimation from 2020-2028 and historical data for 2018 and 2019
  • The market study also provides data on changing market dynamics, market intelligence, current and future market trends
  • The report also analyses the microeconomic and macroeconomic factors that are affecting the global Neuroendocrine Tumor Drug market
  • In-depth analysis of the market’s competitive landscape and detailed information about the vendors
  • The report also offers key market drivers, restrains, trends and opportunities with present and future impact on the market
  • Detailed information about the major players or manufacturers of the global Neuroendocrine Tumor Drug market
  • Comprehensive analysis of the Neuroendocrine Tumor Drug market segments based on its types, applications and end-use industry

Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Neuroendocrine Tumor Drug market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Neuroendocrine Tumor Drug market for numerous purposes such as:

     1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

      2.  Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Neuroendocrine Tumor Drug market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Neuroendocrine Tumor Drug market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

      3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Neuroendocrine Tumor Drug market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Eisai
  • Exelixis, Inc.
  • Foresee Pharmaceuticals, LLC
  • Hutchison MediPharma Limited
  • Intezyne, Inc
  • INVENT Pharmaceuticals, Inc.
  • Ipsen S.A.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Karyopharm Therapeutics, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Midatech Pharma Plc .
  • Millennium Pharmaceuticals, Inc.
  • MolMed S.p.A.
  • Northwest Biotherapeutics, Inc.
  • Novartis AG
  • OctreoPharm Sciences GmbH
  • OXiGENE, Inc.
  • mTOR Protein Inhibitors
  • Tyrosine Kinase 3 Inhibitors
  • Somatostatin Receptor Antagonists
  • Growth Hormone Releasing Factor Antagonists
  • Somatostatin Receptor Agonists
  • Others
  • Hospital
  • Clinic
  • Others

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summary
     2.1. Global Neuroendocrine Tumor Drug Market Snapshot
          2.1.1. Global Neuroendocrine Tumor Drug Market By Type,2019
               2.1.1.1.mTOR Protein Inhibitors
               2.1.1.2.Tyrosine Kinase 3 Inhibitors
               2.1.1.3.Somatostatin Receptor Antagonists
               2.1.1.4.Growth Hormone Releasing Factor Antagonists
               2.1.1.5.Somatostatin Receptor Agonists
               2.1.1.6.Others
          2.1.2. Global Neuroendocrine Tumor Drug Market By Application,2019
               2.1.2.1.Hospital
               2.1.2.2.Clinic
               2.1.2.3.Others
          2.1.3. Global Neuroendocrine Tumor Drug Market By End-use,2019
          2.1.4. Global Neuroendocrine Tumor Drug Market By Geography,2019

3. Global Neuroendocrine Tumor Drug Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Neuroendocrine Tumor Drug Market Size (US$), By Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type, 2020
     4.2. Global Neuroendocrine Tumor Drug Market Size (US$), By Type, 2018 – 2028

5. Global Neuroendocrine Tumor Drug Market Size (US$), By Application, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application, 2020
     5.2. Global Neuroendocrine Tumor Drug Market Size (US$), By Application, 2018 – 2028

6. Global Neuroendocrine Tumor Drug Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Neuroendocrine Tumor Drug Market Size (US$), By End-use, 2018 – 2028

7. Global Neuroendocrine Tumor Drug Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Neuroendocrine Tumor Drug Market Analysis, 2018 – 2028 
          7.2.1. North America Neuroendocrine Tumor Drug Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Neuroendocrine Tumor Drug Market Size (US$), By Type, 2018 – 2028
          7.2.3. North America Neuroendocrine Tumor Drug Market Size (US$), By Application, 2018 – 2028
          7.2.4. North America Neuroendocrine Tumor Drug Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Neuroendocrine Tumor Drug Market Analysis, 2018 – 2028 
          7.3.1.  Europe Neuroendocrine Tumor Drug Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Neuroendocrine Tumor Drug Market Size (US$), By Type, 2018 – 2028
          7.3.3. Europe Neuroendocrine Tumor Drug Market Size (US$), By Application, 2018 – 2028
          7.3.4. Europe Neuroendocrine Tumor Drug Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Neuroendocrine Tumor Drug Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Neuroendocrine Tumor Drug Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Neuroendocrine Tumor Drug Market Size (US$), By Type, 2018 – 2028
          7.4.3. Asia Pacific Neuroendocrine Tumor Drug Market Size (US$), By Application, 2018 – 2028
          7.4.4. Asia Pacific Neuroendocrine Tumor Drug Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Neuroendocrine Tumor Drug Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Neuroendocrine Tumor Drug Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Neuroendocrine Tumor Drug Market Size (US$), By Type, 2018 – 2028
          7.5.3. Latin America Neuroendocrine Tumor Drug Market Size (US$), By Application, 2018 – 2028
          7.5.4. Latin America Neuroendocrine Tumor Drug Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Neuroendocrine Tumor Drug Market Analysis, 2018 – 2028 
          7.6.1.  MEA Neuroendocrine Tumor Drug Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Neuroendocrine Tumor Drug Market Size (US$), By Type, 2018 – 2028
          7.6.3. MEA Neuroendocrine Tumor Drug Market Size (US$), By Application, 2018 – 2028
          7.6.4. MEA Neuroendocrine Tumor Drug Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Neuroendocrine Tumor Drug Providers
        8.4.1 Eisai
                8.1.1 Business Description
                8.1.2 Eisai Geographic Operations
                8.1.3 Eisai Financial Information
                8.1.4 Eisai Product Positions/Portfolio
                8.1.5 Eisai Key Developments
        8.4.2 Exelixis, Inc.
                8.2.1 Business Description
                8.2.2 Exelixis, Inc. Geographic Operations
                8.2.3 Exelixis, Inc. Financial Information
                8.2.4 Exelixis, Inc. Product Positions/Portfolio
                8.2.5 Exelixis, Inc. Key Developments
        8.4.3 Foresee Pharmaceuticals, LLC
                8.3.1 Business Description
                8.3.2 Foresee Pharmaceuticals, LLC Geographic Operations
                8.3.3 Foresee Pharmaceuticals, LLC Financial Information
                8.3.4 Foresee Pharmaceuticals, LLC Product Positions/Portfolio
                8.3.5 Foresee Pharmaceuticals, LLC Key Developments
        8.4.4 Hutchison MediPharma Limited
                8.4.1 Business Description
                8.4.2 Hutchison MediPharma Limited Geographic Operations
                8.4.3 Hutchison MediPharma Limited Financial Information
                8.4.4 Hutchison MediPharma Limited Product Positions/Portfolio
                8.4.5 Hutchison MediPharma Limited Key Developments
        8.4.5 Intezyne, Inc
                8.5.1 Business Description
                8.5.2 Intezyne, Inc Geographic Operations
                8.5.3 Intezyne, Inc Financial Information
                8.5.4 Intezyne, Inc Product Positions/Portfolio
                8.5.5 Intezyne, Inc Key Developments
        8.4.6 INVENT Pharmaceuticals, Inc.
                8.6.1 Business Description
                8.6.2 INVENT Pharmaceuticals, Inc. Geographic Operations
                8.6.3 INVENT Pharmaceuticals, Inc. Financial Information
                8.6.4 INVENT Pharmaceuticals, Inc. Product Positions/Portfolio
                8.6.5 INVENT Pharmaceuticals, Inc. Key Developments
        8.4.7 Ipsen S.A.
                8.7.1 Business Description
                8.7.2 Ipsen S.A. Geographic Operations
                8.7.3 Ipsen S.A. Financial Information
                8.7.4 Ipsen S.A. Product Positions/Portfolio
                8.7.5 Ipsen S.A. Key Developments
        8.4.8 Jiangsu Hengrui Medicine Co., Ltd.
                8.8.1 Business Description
                8.8.2 Jiangsu Hengrui Medicine Co., Ltd. Geographic Operations
                8.8.3 Jiangsu Hengrui Medicine Co., Ltd. Financial Information
                8.8.4 Jiangsu Hengrui Medicine Co., Ltd. Product Positions/Portfolio
                8.8.5 Jiangsu Hengrui Medicine Co., Ltd. Key Developments
        8.4.9 Karyopharm Therapeutics, Inc.
                8.9.1 Business Description
                8.9.2 Karyopharm Therapeutics, Inc. Geographic Operations
                8.9.3 Karyopharm Therapeutics, Inc. Financial Information
                8.9.4 Karyopharm Therapeutics, Inc. Product Positions/Portfolio
                8.9.5 Karyopharm Therapeutics, Inc. Key Developments
        8.4.10 Lexicon Pharmaceuticals, Inc.
                8.10.1 Business Description
                8.10.2 Lexicon Pharmaceuticals, Inc. Geographic Operations
                8.10.3 Lexicon Pharmaceuticals, Inc. Financial Information
                8.10.4 Lexicon Pharmaceuticals, Inc. Product Positions/Portfolio
                8.10.5 Lexicon Pharmaceuticals, Inc. Key Developments
        8.4.11 Midatech Pharma Plc .
                8.11.1 Business Description
                8.11.2 Midatech Pharma Plc . Geographic Operations
                8.11.3 Midatech Pharma Plc . Financial Information
                8.11.4 Midatech Pharma Plc . Product Positions/Portfolio
                8.11.5 Midatech Pharma Plc . Key Developments
        8.4.12 Millennium Pharmaceuticals, Inc.
                8.12.1 Business Description
                8.12.2 Millennium Pharmaceuticals, Inc. Geographic Operations
                8.12.3 Millennium Pharmaceuticals, Inc. Financial Information
                8.12.4 Millennium Pharmaceuticals, Inc. Product Positions/Portfolio
                8.12.5 Millennium Pharmaceuticals, Inc. Key Developments
        8.4.13 MolMed S.p.A.
                8.13.1 Business Description
                8.13.2 MolMed S.p.A. Geographic Operations
                8.13.3 MolMed S.p.A. Financial Information
                8.13.4 MolMed S.p.A. Product Positions/Portfolio
                8.13.5 MolMed S.p.A. Key Developments
        8.4.14 Northwest Biotherapeutics, Inc.
                8.14.1 Business Description
                8.14.2 Northwest Biotherapeutics, Inc. Geographic Operations
                8.14.3 Northwest Biotherapeutics, Inc. Financial Information
                8.14.4 Northwest Biotherapeutics, Inc. Product Positions/Portfolio
                8.14.5 Northwest Biotherapeutics, Inc. Key Developments
        8.4.15 Novartis AG
                8.15.1 Business Description
                8.15.2 Novartis AG Geographic Operations
                8.15.3 Novartis AG Financial Information
                8.15.4 Novartis AG Product Positions/Portfolio
                8.15.5 Novartis AG Key Developments
        8.4.16 OctreoPharm Sciences GmbH
                8.16.1 Business Description
                8.16.2 OctreoPharm Sciences GmbH Geographic Operations
                8.16.3 OctreoPharm Sciences GmbH Financial Information
                8.16.4 OctreoPharm Sciences GmbH Product Positions/Portfolio
                8.16.5 OctreoPharm Sciences GmbH Key Developments
        8.4.17 OXiGENE, Inc.
                8.17.1 Business Description
                8.17.2 OXiGENE, Inc. Geographic Operations
                8.17.3 OXiGENE, Inc. Financial Information
                8.17.4 OXiGENE, Inc. Product Positions/Portfolio
                8.17.5 OXiGENE, Inc. Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Neuroendocrine Tumor Drug Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Neuroendocrine Tumor Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Neuroendocrine Tumor Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Neuroendocrine Tumor Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Neuroendocrine Tumor Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Neuroendocrine Tumor Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Neuroendocrine Tumor Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Neuroendocrine Tumor Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Neuroendocrine Tumor Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Neuroendocrine Tumor Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Neuroendocrine Tumor Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Neuroendocrine Tumor Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Neuroendocrine Tumor Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Neuroendocrine Tumor Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Neuroendocrine Tumor Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Neuroendocrine Tumor Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Neuroendocrine Tumor Drug: Market Segmentation 
FIG. 2 Global Neuroendocrine Tumor Drug Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Neuroendocrine Tumor Drug Market, By Type, 2019 (US$ Mn) 
FIG. 5 Global Neuroendocrine Tumor Drug Market, By Application, 2019 (US$ Mn) 
FIG. 6 Global Neuroendocrine Tumor Drug Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Neuroendocrine Tumor Drug Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Neuroendocrine Tumor Drug Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Neuroendocrine Tumor Drug Providers, 2019
FIG. 11 Global Neuroendocrine Tumor Drug Market Revenue Contribution, By Type, 2019 & 2028 (Value %) 
FIG. 12 Global Neuroendocrine Tumor Drug Market Revenue Contribution, By Application, 2019 & 2028 (Value %) 
FIG. 13 Global Neuroendocrine Tumor Drug Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Neuroendocrine Tumor Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Neuroendocrine Tumor Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Neuroendocrine Tumor Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Neuroendocrine Tumor Drug Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Neuroendocrine Tumor Drug Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Neuroendocrine Tumor Drug market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Neuroendocrine Tumor Drug Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Neuroendocrine Tumor Drug Market Value, By Segment1, 2018 – 2028
TABLE  North America Neuroendocrine Tumor Drug Market Value, By Segment2, 2018 – 2028
TABLE  North America Neuroendocrine Tumor Drug Market Value, By Country, 2018 – 2028
TABLE  Europe Neuroendocrine Tumor Drug Market Value, By Segment1, 2018 – 2028
TABLE  Europe Neuroendocrine Tumor Drug Market Value, By Segment2, 2018 – 2028
TABLE  Europe Neuroendocrine Tumor Drug Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Neuroendocrine Tumor Drug Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Neuroendocrine Tumor Drug Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Neuroendocrine Tumor Drug Market Value, By Country, 2018 – 2028
TABLE  Latin America Neuroendocrine Tumor Drug Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Neuroendocrine Tumor Drug Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Neuroendocrine Tumor Drug Market Value, By Country, 2018 – 2028
TABLE  MEA Neuroendocrine Tumor Drug Market Value, By Segment1, 2018 – 2028
TABLE  MEA Neuroendocrine Tumor Drug Market Value, By Segment2, 2018 – 2028
TABLE  MEA Neuroendocrine Tumor Drug Market Value, By Country, 2018 – 2028
TABLE  Eisai: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Exelixis, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Foresee Pharmaceuticals, LLC: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Hutchison MediPharma Limited: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Intezyne, Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  INVENT Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Ipsen S.A.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Jiangsu Hengrui Medicine Co., Ltd.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Karyopharm Therapeutics, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Lexicon Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Midatech Pharma Plc .: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Millennium Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  MolMed S.p.A.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Northwest Biotherapeutics, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novartis AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  OctreoPharm Sciences GmbH: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  OXiGENE, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Neuroendocrine Tumor Drug Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Neuroendocrine Tumor Drug Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Neuroendocrine Tumor Drug Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Neuroendocrine Tumor Drug Market, By Geography, 2019 (US$ Mn)
FIG.  Global Neuroendocrine Tumor Drug Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Neuroendocrine Tumor Drug Providers, 2016
FIG.  Global Neuroendocrine Tumor Drug Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global mTOR Protein Inhibitors Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Tyrosine Kinase 3 Inhibitors Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Somatostatin Receptor Antagonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Growth Hormone Releasing Factor Antagonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Somatostatin Receptor Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Neuroendocrine Tumor Drug Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Hospital Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Clinic Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Neuroendocrine Tumor Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Neuroendocrine Tumor Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Neuroendocrine Tumor Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Neuroendocrine Tumor Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Neuroendocrine Tumor Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Neuroendocrine Tumor Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Neuroendocrine Tumor Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Neuroendocrine Tumor Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Neuroendocrine Tumor Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Neuroendocrine Tumor Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Neuroendocrine Tumor Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Neuroendocrine Tumor Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Neuroendocrine Tumor Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Neuroendocrine Tumor Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Neuroendocrine Tumor Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Neuroendocrine Tumor Drug Market Value, 2018 – 2028, (US$ Mn)